Avidity Biosciences Inc
NASDAQ:RNA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Avidity Biosciences Inc
NASDAQ:RNA
|
US |
|
Aries Agro Ltd (CN)
BSE:532935
|
IN |
|
Banco do Brasil SA
BOVESPA:BBAS3
|
BR |
|
D
|
Dufu Technology Corp Bhd
KLSE:DUFU
|
MY |
|
Deckers Outdoor Corp
NYSE:DECK
|
US |
|
Premier Pacific Construction Inc
OTC:PPCQ
|
US |
|
C
|
CSPC Pharmaceutical Group Ltd
HKEX:1093
|
CN |
|
M
|
Metech International Ltd
SGX:V3M
|
SG |
|
I
|
Indiabulls Enterprises Ltd
NSE:IEL
|
IN |
|
C
|
CMC Corp
TSE:2185
|
JP |
|
I
|
Intermedical Care and Lab Hospital PCL
SET:IMH
|
TH |
|
SoftBank Corp
TSE:9434
|
JP |
Wall Street
Price Targets
RNA Price Targets Summary
Avidity Biosciences Inc
According to Wall Street analysts, the average 1-year price target for
RNA
is 74.07 USD
with a low forecast of 65.65 USD and a high forecast of 100.8 USD.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.
What is RNA's stock price target?
Price Target
74.07
USD
According to Wall Street analysts, the average 1-year price target for
RNA
is 74.07 USD
with a low forecast of 65.65 USD and a high forecast of 100.8 USD.
What is Avidity Biosciences Inc's Revenue forecast?
Projected CAGR
263%
For the last 1 year the
compound annual growth rate for
Avidity Biosciences Inc's revenue is
71%.
The projected
CAGR
for the next 3 years is
263%.